Document Detail


Myocardial protection by erythropoietin during resuscitation from ventricular fibrillation.
MedLine Citation:
PMID:  17667212     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Human recombinant erythropoietin (rhEPO) can protect the myocardium during ischemia and reperfusion. We investigated whether rhEPO could ameliorate previously identified functional myocardial abnormalities that develop during resuscitation from cardiac arrest, using a rat model of ventricular fibrillation (VF) and closed-chest resuscitation. VF was electrically induced and maintained, untreated, for 10 minutes. Chest compression and ventilation were then started and electrical defibrillation was attempted 8 minutes later. Rats were randomized to receive rhEPO (5000 U/kg) in the right atrium at baseline, 15 minutes before induction of VF (rhEPOBL -15-min), or at 10 minutes of VF, immediately before the start of chest compression (rhEPOVF 10-min), or to receive 0.9% NaCl solution instead (control). rhEPO given at the time of resuscitation (rhEPOVF 10-min group) -- but not at baseline -- prompted more effective chest compression, yielding higher coronary perfusion pressures for a given compression depth (1.95 +/- 0.27 mm Hg/mm; P < 0.05 in comparison with rhEPOBL -15-min [1.63 +/- 0.23 mm Hg/mm] and control [1.62 +/- 0.26 mm Hg/mm], by Dunnett's multicomparison method). Post-resuscitation, rats in the rhEPOVF 10-min group displayed higher mean aortic pressure associated with numerically higher cardiac index, stroke work index, and systemic vascular resistance index. rhEPO may rapidly induce myocardial protection during resuscitation from cardiac arrest.
Authors:
Dinesh Singh; Julieta D Kolarova; Sufen Wang; Iyad M Ayoub; Raúl J Gazmuri
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  American journal of therapeutics     Volume:  14     ISSN:  1075-2765     ISO Abbreviation:  Am J Ther     Publication Date:    2007 Jul-Aug
Date Detail:
Created Date:  2007-08-01     Completed Date:  2007-10-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  361-8     Citation Subset:  IM    
Affiliation:
Advocate Lutheran General Children's Hospital, Park Ridge, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiopulmonary Resuscitation / methods*
Electric Countershock
Erythropoietin, Recombinant / therapeutic use*
Humans
Myocardial Reperfusion Injury / prevention & control*
Rats
Rats, Sprague-Dawley
Ventricular Fibrillation / therapy*
Chemical
Reg. No./Substance:
0/Erythropoietin, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical utility of cardiac troponin I in the diagnosis of acute coronary syndrome in patients with ...
Next Document:  Fractionated neem leaf extract is safe and increases CD4+ cell levels in HIV/AIDS patients.